# Genomic Resilience & Precision Gaps

In the infrastructure of precision medicine, can Africa build sovereign genomic research capacity given its current trial landscape? This registry analysis evaluated the genomic and biomarker trial pipeline across Africa (189 genomic trials, 1,149 biomarker trials) using ClinicalTrials.gov keyword metadata through March 2026. Investigators assessed trial density relative to the continent's estimated 23 biobanks and 51 H3Africa-funded genomic projects as the primary research capacity estimand. Africa's genomic trial rate of 189 registrations represents less than one percent of its 23,873 total trials, compared to a 1.4% genomic rate in the United States. The H3Africa initiative has built foundational capacity, but local sequencing and bioinformatics infrastructure remains insufficient for independent pharmacogenomic discovery. Without sovereign genomic infrastructure, African genetic data flows to Northern laboratories while precision medicine benefits remain inaccessible. These results frame genomic sovereignty as the critical bottleneck for equitable global health innovation. Interpretation is limited by the exclusion of observational genomic studies from the interventional trial registry.

## References

1. Munung NS, et al. "Obtaining informed consent for genomics research in Africa." BMC Med Ethics. 2016;17:15.
2. Popejoy AB, Fullerton SM. "Genomics is failing on diversity." Nature. 2016;538:161-164.
3. H3Africa Consortium. "Research capacity for genomics in Africa." Science. 2014;344:1346-1348.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/health-disease/dashboards/genomic-resilience.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/health-disease/code/genomic-resilience.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05